BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.
Oppenheimer 33rd Annual Healthcare Conference:
| Location: | Virtual |
| Format: | Fireside chat and one-on-one meetings |
| Date: | March 13-15, 2023 |
| Fireside chat: | March 13, 10:00am ET |
| Presenter: | Spiro Rombotis |
| Webcast: | Link |
35th Annual Roth Conference:
| Location: | Dana Point, CA |
| Format: | Fireside chat and one-on-one meetings |
| Date: | March 12-14, 2023 |
| Fireside chat: | March 13, 3:00pm PT |
| Presenter: | Paul McBarron |
| Webcast: | Link |
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Contacts
| Company: | Paul McBarron, (908) 517-7330, This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Investor Relations: | Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681, This email address is being protected from spambots. You need JavaScript enabled to view it. |
© Copyright 2023 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
| Last Trade: | US$1.65 |
| Daily Change: | 0.05 3.12 |
| Daily Volume: | 35,255 |
| Market Cap: | US$10.380M |
May 15, 2025 April 02, 2025 March 24, 2025 February 27, 2025 November 14, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
